Tecott L H, Kwong L L, Uhr S, Peroutka S J
Biol Psychiatry. 1986 Oct;21(12):1114-22. doi: 10.1016/0006-3223(86)90219-2.
Chronic administration of the neuroleptic haloperidol, the calcium channel antagonist nitrendipine, and the calcium channel antagonist neuroleptic pimozide produce differential effects on rat striatal 3H-spiperone binding. Following 7 days of 10 mg/kg i.p. administration, haloperidol significantly increases (p less than 0.01) dopamine D2 receptor binding to 123% +/- 6% of control values, whereas pimozide treatment significantly reduces (p less than 0.001) striatal 3H-spiperone binding to 46% +/- 6% of control values. Chronic administration of the calcium channel antagonist nitrendipine does not alter 3H-spiperone binding relative to control values. Saturation analysis reveals an increase in Bmax following chronic haloperidol and a decrease in Bmax following chronic pimozide treatment. No alterations in muscarinic cholinergic sites, dopamine uptake sites, or calcium channel antagonist sites result following chronic drug administration. These results are the first demonstration of a decrease in dopamine D2 binding sites after chronic neuroleptic treatment.
长期给予抗精神病药物氟哌啶醇、钙通道拮抗剂尼群地平和钙通道拮抗剂抗精神病药物匹莫齐特,对大鼠纹状体3H-螺哌隆结合产生不同影响。腹腔注射10mg/kg,持续7天后,氟哌啶醇显著增加(p<0.01)多巴胺D2受体结合,达到对照值的123%±6%,而匹莫齐特治疗显著降低(p<0.001)纹状体3H-螺哌隆结合,降至对照值的46%±6%。与对照值相比,长期给予钙通道拮抗剂尼群地平不会改变3H-螺哌隆结合。饱和分析显示,长期给予氟哌啶醇后Bmax增加,长期给予匹莫齐特后Bmax降低。长期给药后,毒蕈碱胆碱能位点、多巴胺摄取位点或钙通道拮抗剂位点均无改变。这些结果首次证明了长期抗精神病药物治疗后多巴胺D2结合位点减少。